US Pharma MarketingIpsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3 is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Ipsen has shared phase 2 data on its long-acting neurotoxin, reporting an increase in the proportion of people with significant improvements in frown lines 24 weeks after treatment.
Source: FierceBiotech